Inflammation Mediated Alterations in the Iron Homeostasis of Eales’ Disease

Muthuvel Bharathselvi (✉️ bharathselvi363@gmail.com )
Vision Research Foundation

Konerirajapuram N Sulochana
Vision Research Foundation

Ramanujam Saravanan
Vision Research Foundation

Jyothirmay Biswas
Vision Research Foundation

Research Article

Keywords: Eales’ disease, Idiopathic retinal vascular disease, iron transport, hepcidin

Posted Date: February 9th, 2022

DOI: https://doi.org/10.21203/rs.3.rs-1334699/v1

License: ©️ This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background: Eales’ Disease is an idiopathic retinal periphlebitis, characterized by recurrent vitreous hemorrhage, neovascularization and inflammation. The disease distresses the retina of adult males between 15 and 45 years. In the present study proteins involved in iron homeostasis were assessed in serum and peripheral blood mononuclear cells.

Methods: Forty male subjects, were recruited for the study. Their blood samples were used to measure the ferritin, transferrin, soluble transferrin receptor, hepcidin, ferroportin and heme. Besides ALAS, HO, HIF-2 and other relevant parameters were also measured.

Results: In the ED group, significantly increased in the levels of heme, heme oxygenase, ferritin and VEGF were observed in serum and monocytes of ED, besides decrease in the levels of transferrin. Interestingly, the expression levels of hepcidin and HIF were increased whereas the ferroportin was found to be decreased.

Conclusions: These results propose an evidence for the involvement of altered iron homeostasis.

Introduction

Eales' disease (ED), characterized as an idiopathic, inflammatory veno-occlusive disease, which affects, the peripheral retinal veins especially of young males \(^{(1,2)}\). The disease is found to be, prevalent in Indian subcontinent with an incidence rate of 1 in 200-250 ophthalmic patients \(^{(3-5)}\). ED presents with periphlebitis that causes retinal ischemia and persistent ischemia leads to retinal neovascularization and consequential blindness \(^{(6)}\). Although, ED is associated with multiple causes, its etiopathogenesis is not clearly known, till date \(^{(7)}\). Among various causes, notable changes in iron homeostasis was observed in patients with ED viz., increased ferric (Fe\(^{3+}\)) to ferrous (Fe\(^{2+}\)) ion ratio in the serum and increased levels of iron in vitreous and monocytes, of patients with ED \(^{(8,9)}\). Apart from ED; iron is also, involved in various other ocular diseases, like age related macular degeneration (AMD), cataract, glaucoma conditions which results in intraocular hemorrhage \(^{(10)}\). Moreover, iron is a potent producer of most reactive hydroxyl radicals and can be the reason, for the considerable oxidative stress. Oxidative stress, hydroxyl radicals and decreased antioxidants levels were reported in vitreous, serum and monocytes obtained from ED patients \(^{(9-11)}\). The increased level of advanced glycation end product - carboxy methyl lysine also, confirms the involvement of iron induced glycoxidation in Eales’ disease \(^{(12)}\). Further a novel 88 kDa proteins, present in serum and vitreous of ED patients, characterized to be a glycoprotein with iron binding capacity and antioxidant role \(^{(12)}\).

Dietary iron; imported by the DMT1 (Divalent metal transporter-1) which is expressed on the apical side of absorptive cells, is reduced from Fe\(^{3+}\) to Fe\(^{2+}\) form by duodenal cytochrome B \(^{(10)}\). The iron thus, imported is either stored in cytosolic iron-storage molecule ferritin or secreted into plasma by the basolateral iron exporter ferroportin \(^{(13)}\). The plasma enzymes ceruloplasmin and hephaestin reconvert Fe\(^{2+}\) to Fe\(^{3+}\) that bind to transferrin and transferred to heme group. In case of iron overload; hepcidin, a regulatory protein of iron absorption, triggers the degradation of ferroportin, thereby, preventing release of excess iron into the circulation \(^{(14,15)}\).

It is noteworthy that, hepcidin, a key regulator of iron homeostasis \(^{(15)}\) is induced as a result of inflammation, a key factor involved in the pathogenesis of ED. To understand the relevance of iron homeostasis and its deviation in pathophysiology of ED, there exists a need to decipher the functionality of proteins involved in iron metabolism. Therefore, the study aims to unravel the derangement in iron metabolism in ED patients, by using serum
and PBMCs from case and control subjects and this study, is first of its kind to provide insights in the understanding of the iron-mediated etiopathology of the disease.

**Materials And Methods**

**Patients**

Twenty patients with ED, of unknown etiology (as diagnosed after detailed fundus examination by an ophthalmologist), and twenty healthy adult volunteers were recruited for the study. ED was diagnosed based on clinical features such as vasculitis, vitreous hemorrhage, peribhlebitis, vascular sheathing, peripheral nonperfusion, presence of floaters and decrease in visual acuity. The demographic details of the patients are given in table 1. All forty test subjects were males, between the ages of 15 and 45, and were generally healthy. None of them were smokers or alcoholics or taking vitamin supplements. The authors’ Institute's Research Board and Ethics Committee approved this study. Informed written consent for participating in the study was obtained from all participants. All experiments pertaining to human subjects were performed in adherence to the tenets of the Helsinki declaration.

**Table 1:** Demographic details of the patients
| S. NO | Age/Sex | Clinical Diagnosis                                                                 | Medications at time of collection |
|-------|---------|------------------------------------------------------------------------------------|-----------------------------------|
|       |         | Patients                                                                           |                                   |
| 1     | 25/M    | active vasculitis, cotton wool spot (OD,OS)                                        | Nil                               |
| 2     | 20/M    | active vasculitis, vitreous hemorrhage                                             | Nil                               |
| 3     | 21/M    | active vasculitis, vitreous hemorrhage                                             | Nil                               |
| 4     | 26/M    | OD-perivasculitis, choroiditis                                                     | Nil                               |
| 5     | 20/M    | active vasculitis, vitreous hemorrhage, ED                                         | Nil                               |
| 6     | 43/M    | Vasculitis                                                                         | Nil                               |
| 7     | 18/M    | Active vasculitis, dispersed vitreous hemorrhage                                   | Nil                               |
| 8     | 32/M    | Vitreous hemorrhage, healed vasculitis                                             | Nil                               |
| 9     | 42/M    | Vasculitis, mild vitreous hemorrhage                                               | Nil                               |
| 10    | 33/M    | active vasculitis, neovascularization                                              | Nil                               |
| 11    | 23/M    | active vasculitis, vitreous hemorrhage, Bronchial tuberculosis                      | Nil                               |
| 12    | 30/M    | active vasculitis, vitreous hemorrhage                                             | Nil                               |
| 13    | 42/M    | peripheral vasculitis, vitreous hemorrhage, phlebitis, healed vasculitis            | Nil                               |
| 14    | 28/M    | active vasculitis, vitreous exudates, ED                                           | Nil                               |
| 15    | 15/M    | active vasculitis, vitreous hemorrhage                                             | Nil                               |
| 16    | 23/M    | active vasculitis, hemorrhage                                                       | Nil                               |
| 17    | 43/M    | active vasculitis, vitreous hemorrhage                                             | Nil, prednisone                   |
| 18    | 17/M    | active vasculitis, vitreous hemorrhage                                             | Nil                               |
| 19    | 30/M    | periphlebitis                                                                       | Nil                               |
| 20    | 17/M    |                                                                                  | Nil                               |
|       |         | Controls                                                                           |                                   |
|       |         | 20 healthy volunteers with the age group of 27.5 ± 0.9                              | Nil                               |

**Sample collection**

From each participant, 12 ml of blood sample was collected. In the 4 ml blood sample was collected in plain tubes and serum was separated from blood cells by centrifugation at 3000 g at 25°C for 10 minutes, aliquoted and stored at -80°C for further analysis. 8 ml of heparinized blood sample was collected and monocytes were isolated by ficoll density gradient centrifugation.
Biochemical parameters analyzed in serum sample were as follows; heme, aminolevulinic acid synthase, heme oxygenase, ferritin, transferrin, soluble transferrin receptor and VEGF by following various methods described below. Parameters analysed in monocytes included ferritin, heme, heme oxygenase, aminolevulinic acid synthase and VEGF. RNA was isolated and mRNA expression of hepcidin, ferroportin, and HIF2α were quantified by Q-PCR.

**Determination of Heme, Heme oxygenase activity (HO) and Aminolevulinic acid synthase (ALAS)**

Heme content in serum and monocytes was determined using colorimetric determination at 400 nm by using a QuantiChrom Heme assay kit described by Berry et al., (16) (Bio Assay Systems, Hayward, CA, USA). The concentration of heme was expressed as µM in serum and µm / mg of protein in monocytes. HO activity assay in serum and monocytes was performed by using the method described by Bussolati et al., (17). The specific activity of HO was expressed as pmoles of bilirubin formed / mg of protein / h in serum and monocytes (17). Aminolevulinic acid synthase activity in serum and monocytes was performed by the method described by Hunter et al., (18). The concentration of ALAS was expressed as U/L in serum and units/mg protein in monocytes.

**Determination of Ferritin, Transferrin and soluble transferrin receptor**

Ferritin in serum and monocytes were determined by turbidimetry method described by Bernard (19). The concentration of ferritin in serum and monocytes were expressed as µg/L in serum and in monocytes µg/mg of protein. Transferrin in serum was determined by turbidimetry method described by Kreutzer (20) and the concentration of transferrin in serum was expressed as mg/dL and soluble transferrin receptor was performed by the method of enzyme linked immunosorbent assay described by Samuelson (21) and the concentration of serum transferrin receptor in serum was expressed as mg/L (ELISA, BioVendor, Canada).

**Determination of Vascular endothelial Growth Factor (VEGF)**

VEGF in serum and monocytes was determined by using Quantikine VEGF Immunoassay kit (R&D, USA) in accordance with the manufacturer's instructions. The concentration of VEGF in serum was expressed as pg/mL and in monocytes was expressed as pg/mg of proteins. The optical density of well was determined using a microplate reader at 450 nm.

**Isolation of total RNA, reverse transcriptase and real-time PCR assays**

RNA was extracted by using TRIZOL reagent (sigma), cDNA quality and concentration were estimated by optical density using Nanodrop1000 (Thermo Scientific, Wilmington, DE). Quantitative real-time PCR assays were developed using RNA Master SYBR Green Kit according to the manufacturer's protocol using Applied Bio systems (22) (Foster City, CA). Levels of hepcidin, ferroportin and hypoxia inducible factor - HIF 2α were determined and the details of primers given in table 2. The $2^{-\Delta\Delta Ct}$ method was used to estimate relative transcript levels with GAPDH as endogenous control. Relative quantification data were obtained using ABI prism 7000 SDS software. The PCR reactions were set in triplicate, the mean values used for calculations.

**Table 2: RT- PCR primers**
| S.NO | Gene Name   | Accession number | Forward primer                        | Reverse primer                        |
|------|-------------|------------------|---------------------------------------|---------------------------------------|
| 1    | Hepcidin    | NM_021175.2      | 5′GACACCCACTTCCCCATCTG3′              | 5′ GCAGGGCAGGTAGTTCTAC3′              |
| 2    | Ferroportin | NM_014585.5      | 5′ TTGGGGAGATCGGATGTGGC 3′           | 5′ GTCACCGATGATGGCTCCCA 3′           |
| 3    | HIF 2 α     | NM_001430.4      | 5′AGGTGGAGCTAACAGGACATAG3′           | 5′GCTGACTTGAGGTTGACAGTAC3′           |
| 4    | GAPDH       | NM_002046        | 5′GCCAAGGTCATCCATGACAAC 3′           | 5′GTCCACCACCTGTGCTGTA 3′             |

Statistics

All values were expressed as mean ± standard error mean. With SPSS software, (version: 16.0) the raw data were analyzed for statistical significance using student “t” test. P value of < 0.05 was considered significant.

Results

Increased levels of ALAS, Heme, Heme oxygenase and VEGF

The serum and intracellular levels of ALAS, Heme, Heme oxygenase and VEGF are given in table 3 and figure 1. Since serum haemoglobin was more in ED, may be of excess production or breakdown of haemoglobin. To address this, we measured ALAS. There was a significant increased levels of serum ALAS, Heme, HO and VEGF in ED patients compared to the control subjects (p < 0.013, p < 0.0001, p < 0.0001 and p < 0.001). Besides significant increase in the levels of intracellular ALAS, Heme, HO and VEGF in ED patients were observed to the control subjects (p < 0.001, p < 0.001, p < 0.001 and p < 0.002). There was a positive correlation between the serum heme and serum ALAS in ED patients (r = 0.5018, p < 0.040) (figure 1e) and also a positive correlation between the serum ALAS and serum VEGF in ED patients (r = 0.4806, p < 0.032) (figure 1f). There was a positive correlation between serum HO and VEGF in both subjects (such as ED and control) (r = 0.520, p < 0.001) and also a positive correlation between serum ALAS and HO in both subjects (such as ED and control) (r = 0.647, p < 0.001). In intracellular also we observed a positive correlation between the heme and ALAS in ED patients (r = 0.514, p<0.01), and also a positive correlation between the HO and VEGF intracellular in ED patients (r = 0.543, p < 0.001).

Table 3: Intracellular Levels of Biochemical parameters measured in control and Eales’ disease subjects.

| Biochemical Parameters                          | Control subjects (n = 20) | Eales’ disease (n = 20) | P value |
|------------------------------------------------|---------------------------|-------------------------|---------|
| Ferritin (µg / mg of proteins)                  | 20.9 ± 1.4                | 65.7 ± 2.5              | 0.001   |
| Heme (µm / mg of proteins)                      | 8.9 ± 1.7                 | 27.2 ± 5.1              | 0.001   |
| Heme oxygenase (pmoles of bilirubin / mg protein)| 1.5 ± 0.2                | 6.4 ± 0.5               | 0.001   |
| Aminolevulinic acid synthase ( U / mg of proteins) | 2.4 ± 0.2                | 12.5 ± 3.0              | 0.001   |
| Vascular endothelial growth factor (pg/mg of proteins) | 29.8 ± 4.0              | 147.5 ± 40.2            | 0.005   |

Levels of Ferritin, Transferrin and Soluble transferrin receptor
We measured the levels of serum ferritin, serum transferrin and soluble transferrin receptor levels in study subjects. The results are given in figure 2. There was a significant increase in the levels of serum and intracellular ferritin (table 3) in ED patients compared to the controls (p < 0.002, p < 0.001) and there was a significantly decreased serum transferrin levels in ED patients compared to the controls (p < 0.02). There was a negative correlation between the serum ferritin and serum transferrin in ED patients (r = -0.50, p < 0.03) (figure 2d) and this correlation was similar in analyzed both controls and ED together.

**Expression of Iron regulators**

Why there is an increased intracellular ferritin levels, in ED subjects, provoking interest in knowing the status of iron regulators, their role in the disease and hence to measure the mRNA expression of hepcidin an iron sensor and ferroportin an iron exporter. The mRNA expression of hepcidin was up regulated and ferroportin was down regulated in ED patients when compared to the controls (figure 3). Thus, the result shows a potential role for that hepcidin in ED. This increase in the expression of hepcidin may be due to increased iron, inflammation or infection. It is known that hepcidin can bind to ferroportin, triggering its internalization and degradation resulting in the accumulation of intracellular iron in the form of ferritin.

**Over expression of Hypoxia inducible factor (HIF2 α)**

Since, both VEGF and HO are elevated in ED; it is of interest to know further on the status of hypoxia inducible proteins. Hence, the expressions of hypoxia (HIF 2) were measured. The mRNA expression of HIF 2 was up regulated in ED compared to the controls as shown (figure 3).

**Discussion**

The aetiopathogenesis of ED is not clearly known. However, recently literature associated ED with tuberculosis, but still now the active organism was not cultivated. The disease still remains idiopathic, with no diagnostic test available in the lab. Direct evidence of infection is not made. Similar to homocysteine, Iron also act as an independent risk factor of cardiovascular diseases. Roest [23] observed increased iron stores leads to cardiovascular diseases similar to that of hyperhomocysteine. Sullivan [24] observed that increased iron stores leads to endothelial dysfunction and that elevated homocysteine is dependent on iron overload. This excess iron generates free hydroxyl radical and causes oxidative stress through Fenton reaction. Schiepers [25] observed that changes in both homocysteine and ferritin levels in cardiovascular disease. The serum ferritin is frequently used as a measure of iron stores. The present findings indicate iron storage since; there is an elevated level of ferritin and lowered transferrin in ED. It is known that, red cell breakdown can occur outside or inside the vascular compartment in ED. Increased serum haemoglobin in ED indicates the vascular damage due to intra vascular and extra vascular hemolysis. Extra vascular hemolysis are occur due to phagocytosis whereas intravascular hemolysis as a result of mechanical injury and toxic factors. Heme is the prosthetic group of heme proteins such as haemoglobin, is an essential molecule plays a crucial role in cell differentiation and other functions. Free heme namely unbound heme can be toxic to cells, because it results in production of reactive oxygen species and causes cell damage. The absolute levels of Heme are regulated by its biosynthesis and catabolism. Heme biosynthesis is regulated by ALAS and its degradation to Fe, bilirubin and CO is catalyzed by HO, in this study, it is observed that both the enzymes are elevated in ED.

Heme oxygenase plays an important role in regulating the heme level by catalyzing the initial and rate limiting step of heme degradation and resulting in the formation of carbon monoxide, iron and bilirubin. Heme oxygenase exists as three isoforms; HO-1, HO-2 and HO-3. HO-1, the inducible 32-kDa isoform, HO-2, the constitutive 36-kDa isoform, and
HO-3, has no activity and is not expressed in humans. The HO-1 is a member of the heat shock proteins, and its expression is influenced by hypoxia (26), heavy metals, ROS such as $\text{H}_2\text{O}_2$ (27), reactive nitrogen oxides (28), TNF α, interleukin β and interferon Y (29). The biological functions of HO-1 are associated against oxidative and cellular stress. HO-1 represents a crucial mediator of antioxidants and possesses anti-inflammatory and anti-apoptotic properties (30). L’Abbate et al., and Bharathselvi et al., (31, 32) have shown that induction of HO-1 was associated with a parallel increase in the serum levels of adiponectin, which has a well documented anti-inflammatory property. The peroxisome proliferator-activated receptor (PPAR-Y) regulates the expression of HO in human vascular cells (33).

Over expression of HO-1 contributes in the revascularization of damaged tissue. In terms of neovascularization, HO-1 having a pro-angiogenic, anti-inflammatory and anti-apoptotic enzyme in regulation of wound healing (34, 35). Product of HO activity the bilirubin is a powerful antioxidant thereby, protecting the retinal cells. However, during haemorrhage, the iron and bilirubin excessively produced and are neurotoxic, have deleterious consequences. HO-1 is an inducible enzyme whose activity increases in response to iron as well as heme, light, oxidative stress, and inflammation. The main condition for the initiation of neovascularization is hypoxia (36). Hypoxia-inducible factor activates several genes related to iron metabolism such as HO-1, endothelin-1, transferrin, transferrin receptor and ceruloplasmin (36).

HO, cleavage of the heme ring will release intracellular iron, which in turn increases the stimulation of ferritin. Dulak et.al observed that HO plays an important role in angiogenesis during hypoxia, similarly nitric oxide synthase, by VEGF production (37). Alternately VEGF can stimulate HO-1 to promote angiogenesis and inhibiting leukocyte adhesion and transmigration (17). In the present study, it's observed that both HO and VEGF increased due to inflammation and non-inflammatory responses.

Hepcidin, a circulating peptide hormone is mainly synthesized by the liver hepatocytes, and also in eye plays a major role in regulating iron homeostasis in the body (38). The mature form is 25 amino acids with four inter subunit disulfide bonds. The massive iron overload found in hepcidin knock-out mice suggests that hepcidin is an iron stores regulator involved in communication of body iron status to the intestine and also in the retinal pigment epithelial cells (38). The mechanism of hepcidin activity depends on hepcidin interactions with ferroportin. Ferroportin is the only known mammalian cellular iron exporter. Hepcidin regulates post translational ferroportin expression (38). Hepcidin binds to ferroportin and causes its internalization and degradation in turn blocks the iron transport via ferroportin (38). Hepcidin is reported to be elevated in chronic inflammation condition, anemia, more specifically wherein iron accumulates inside the cells (39).

Hepcidin synthesized can be induced by inflammatory cytokine IL-6, inflammation, and infection (40)[Prentice, 2012 #102]. IL-6 acts via its receptor and causes phosphorylation of signal transducer and activator of transcription 3 (STAT 3), STAT3 activation requires the presence of SMAD 4 to affect the HAMP gene expression (39). Under normal conditions HAMP gene expression is regulated by BMP/SMAD and STAT3 pathways. Another hepatocyte iron sensors activating hepcidin synthesis are hemochromatosis protein (HFE) and transferrin receptor 2 (TFR2) (39).

Due to an intracellular storage of iron, there is an increased production of hepcidin. In the present study, there is an increased storage of ferritin levels and up regulation of hepcidin. Inflammation leads to cellular iron sequestering through IL-6 up regulation of hepcidin. Iron can be export from the cell with the help of iron exporter ferroportin. In the present study, we also observed that hepcidin expression was increased and ferroportin was decreased in ED compared to controls. Interestingly cellular iron accumulation caused diminished ferroportin after hepcidin binding. There is an increased expression of hepcidin may be due to increased iron, inflammation and infection. Importantly, a cellular iron act as a cofactor of HIF, in the present study, it shows that there is an increased expression of HIF2α.
previous report says that hypoxia is a negative regulator of hepcidin expression (39), but in the present study, shows that HIF 2α expression was increased in ED may be due to inflammation and also by IL-6. The interaction between hepcidin and ferroportin binding is a key step to control an iron homeostasis.

From the present study, we conclude that increased serum and intracellular ferritin, heme and HO, hepcidin play an important role in the vasculitis. The present study establishes the role for iron in disease pathogen. In our study thus the increased levels of these proteins may be due to an infection and inflammation conditions. The real significance of these findings needs to be understood in an animal model or an in-vitro cell culture experiments.

**Abbreviations**

ED - Eales' Disease
Hcy - Homocysteine
Hb - Haemoglobin;
HO - Heme oxygenase;
VEGF- Vascular endothelial growth factor;
ALAS - aminolevulinic acid Synthase;
IL - Interleukin;
Hep - Hepcidin;
FPN - Ferroportin.

**Declarations**

**Ethical approval:**

Institutional Ethics committee.

**Consent to participate:**

Informed written consent for participating in the study was obtained from all participants. All experiments pertaining to human subjects were performed in adherence to the tenets of the Helsinki declaration.

**Availability of data and materials:**

Data and materials are in the manuscript.

**Competing interests:**

No conflict of interest.

**Funding:**

Supported by Grant from (ICMR) Indian council of Medical research – ICMR/53/18/2009-BMS.
Authors' Contributions:

MB processing the sample analyzed the data and wrote the paper, RS processing the sample; KNS conceived the work, analyzed the data and wrote the paper. JB was the ophthalmic consultant who treated the patients, obtained their consent, recruited and in filling the clinical proforma in this study.

Acknowledgement:

We thank the Indian Council of Medical research (ICMR) for their funding.

References

1. Biswas J, Sharma T, Gopal L, Madhavan HN, Sulochana KN, Ramakrishnan S. Eales disease—an update. Survey of ophthalmology 2002; 47(3):197–214.
2. Eales H. Retinal haemorrhages associated with epistaxis and constipation. 1980; 9: 262.
3. Putamma ST. Varied fundus picture of central retinal vasculitis. Trans Asia Pacific Acad Ophthalmol 1970; 3:520.
4. Awasthi P, Mehrotra M, Srivastava SN. Ocular conditions in pulmonary tuberculosis patients in India. Acta XX Concilium Ophthalmologicum 1966; 1025.
5. Badrinath SS, Honnatti MR. Vitrectomy in Eales’ disease. Acta Int Cong Ophthalmol 1982; 24:536.
6. Saxena S, Kumar D. A new staging system for idiopathic retinal periphlebitis. European journal of ophthalmology 2004; 14(3):236–9.
7. Das T, Pathengay A, Hussain N, Biswas J. Eales’ disease: diagnosis and management. Eye 2010; 24(3):472–82.
8. Selvi R, Angayarkanni N, Bharathselvi M, Sivaramakrishna R, Anisha T, Jyotirmoy B et al. Increase in Fe3+/Fe2+ ratio and iron-induced oxidative stress in Eales disease and presence of ferrous iron in circulating transferrin. Current eye research 2007; 32(7-8):677–83.
9. Rajesh M, Sulochana KN, Ramakrishnan S, Biswas J, Manoharan PT. Iron chelation abrogates excessive formation of hydroxyl radicals and lipid peroxidation products in monocytes of patients with Eales’ disease: direct evidence using electron spin resonance spectroscopy. Current eye research 2004; 28(6):399–407.
10. Loh A, Hadziahmetovic M, Dunaief JL. Iron homeostasis and eye disease. Biochimica et biophysica acta 2009; 1790(7):637-49.
11. Konerirajapuram NS, Coral K, Punitham R, Sharma T, Kasinathan N, Sivaramakrishnan R. Trace elements iron, copper and zinc in vitreous of patients with various vitreoretinal diseases. Indian journal of ophthalmology 2004; 52(2):145–8.
12. Rajesh M, Sulochana KN, Sundaram AL, Krishnakumar S, Biswas J, Ramakrishnan S. Presence of a 88 kDa Eales protein in uveitis, tuberculosis, leprosy and rheumatoid arthritis. Medical science monitor : international medical journal of experimental and clinical research 2003; 9(2):95-9.
13. Rouault TA. Post-transcriptional regulation of human iron metabolism by iron regulatory proteins. Blood cells, molecules & diseases 2002; 29(3):309–14.
14. Vanarsa K, Ye Y, Han J, Xie C, Mohan C, Wu T. Inflammation associated anemia and ferritin as disease markers in SLE. Arthritis research & therapy 2012; 14(4):R182.
15. Atanasiu V, Manolescu B, Stoian I. Hepcidin—central regulator of iron metabolism. European journal of haematology 2007; 78(1):1–10.
16. Berry EA, Trumpower BL. Simultaneous determination of hemes a, b, and c from pyridine hemochrome spectra. Anal Biochem. 1987; 161:1-15.
17. Bussolati B, Ahmed A, Pemberton H, et al. Bifunctional role for VEGF-induced heme oxygenase-1 in vivo: induction of angiogenesis and inhibition of leukocytic infiltration. Blood. 2004;103:761-766.

18. Hunter GA, Ferreira GC. A continuous spectrophotometric assay for 5-aminolevulinate synthase that utilizes substrate cycling. Anal Biochem. 1995;226:221-224.

19. Bernard A, Lauwerys R. Turbidimetric latex immunoassay for serum ferritin. J Immunol Methods. 1984;71:141-147.

20. Kreutzer HJ. An immunological turbidimetric method for serum transferrin determination. J Clin Biochem. 1976;14:401-406.

21. Samuelson G, Lonnerdal B, Kempe B, Elverby JE, Bratteby LE. Serum ferritin and transferrin receptor concentrations during the transition from adolescence to adulthood in a healthy Swedish population. Acta Paediatr. 2003;92:5-11.

22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods. 2001;25:402-408.

23. Roest M, van der Schouw YT, de Valk B, et al. Heterozygosity for a hereditary hemochromatosis gene is associated with cardiovascular death in women. Circulation. 1999;100:1268-1273.

24. Sullivan JL. Is homocysteine an iron-dependent cardiovascular risk factor? Kidney Int. 2006;69:642-644.

25. Schiepers, O.J., et al., Serum iron parameters, HFE C282Y genotype, and cognitive performance in older adults: results from the FACIT study. J Gerontol A Biol Sci Med Sci.2010;65(12):1312-21.

26. Motterlini R, Macdonald VW. Cell-free hemoglobin potentiates acetylcholine-induced coronary vasoconstriction in rabbit hearts. J Appl Physiol. 1993;75(5):2224-33.

27. Keyse SM, Tyrrell RM. Heme oxygenase is the major 32-kDa stress protein induced in human skin fibroblasts by UVA radiation, hydrogen peroxide, and sodium arsenite. Proceedings of the National Academy of Sciences of the United States of America. 1989;86(1):99-103.

28. Hara E, Takahashi K, Takeda K, Nakayama M, Yoshizawa M, Fujita H, et al. Induction of heme oxygenase-1 as a response in sensing the signals evoked by distinct nitric oxide donors. Biochemical pharmacology. 1999;58(2):227-36.

29. Willis D, Moore AR, Frederick R, Willoughby DA. Heme oxygenase: a novel target for the modulation of the inflammatory response. Nature medicine. 1996;2(1):87-90.

30. Cao J, Drummond G, Inoue K, Soda K, Li XY, Omura S. Upregulation of heme oxygenase-1 combined with increased adiponectin lowers blood pressure in diabetic spontaneously hypertensive rats through a reduction in endothelial cell dysfunction, apoptosis and oxidative stress. International journal of molecular sciences. 2008;9(12):2388-406.

31. L’Abbate A, Neglia D, Vecoli C, Novelli M, Ottaviano V, Baldi S, et al. Beneficial effect of heme oxygenase-1 expression on myocardial ischemia-reperfusion involves an increase in adiponectin in mildly diabetic rats. American journal of physiology. 2007;293(6):H3532-41.

32. Bharathselvi Muthuvel, Vidhya Srinivasan, Pukhraj Rishi, Sulochana N. Konerirajapuram. Increased Vitreous Heme Oxygenase Activity is Associated with Proliferative Diabetic Retinopathy. Ind J Clin Biochem.2015.30(4), 418-423.

33. Kronke G, Kadl A, Ikonomu E, Bluml S, Furnkranz A, Sarembock IJ, et al. Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors. Arteriosclerosis, thrombosis, and vascular biology. 2007;27(6):1276-82.
34. Peterson SJ, Frishman WH, Abraham NG. Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system. Cardiology in review. 2009;17(3):99-111.
35. Abraham NG, Kappas A. Pharmacological and clinical aspects of heme oxygenase. Pharmacological reviews. 2008;60(1):79-127.
36. Ciudin A, Hernandez C, Simo R. Iron overload in diabetic retinopathy: a cause or a consequence of impaired mechanisms? Experimental diabetes research. 2010: 1-8.
37. Dulak J, Jozkowicz A. Regulation of vascular endothelial growth factor synthesis by nitric oxide: facts and controversies. Antioxidants & redox signaling. 2003;5(1):123-32.
38. Prentice AM, Doherty CP, Abrams SA, Cox SE, Atkinson SH, Verhoef H, et al. Hepcidin is the major predictor of erythrocyte iron incorporation in anemic African children. Blood. 2012;119(8):1922-8.
39. Martinelli N, Traglia M, Campanini N, Biino G, Corbella M, Sala C, et al. Increased serum hepcidin levels in subjects with the metabolic syndrome: a population study. PloS one. 2012;7(10):e48250.
40. Prentice AM, Cox SE. Iron and malaria interactions: research needs from basic science to global policy. Adv Nutr. 2012;3(4):583-91.

Figures

**Figure 1**
Comparison of serum Heme, aminolevulinic acid synthase, Heme oxygenase (HO) and VEGF among ED and healthy controls. Statistical significance between control (n = 20) and ED (n = 20), a) Heme p < 0.013*, b) aminolevulinic acid synthase p < 0.0001**, c) HO p < 0.0001**, d) VEGF p < 0.001*.

Correlation between serum aminolevulinic acid synthase, serum Heme, and serum VEGF in ED and controls, e) Positive correlation between serum Heme and aminolevulinic acid synthase (r = 0.50018, p < 0.040*), f) Positive correlation between serum aminolevulinic acid synthase and VEGF (r = 0.4806, p < 0.032*).

**Figure 2**
Comparison of serum ferritin, Transferrin and soluble transferrin receptor among ED and healthy controls. Statistical significance between control (n = 20) and ED (n = 20),

a) Serum ferritin p < 0.002**; b) serum Transferrin significantly decreased in ED compare to control p < 0.02*; c) Soluble transferrin receptor p = 0.477.

d) Negative correlation between serum ferritin and serum Transferrin in ED and controls, (r = -0.50, p < 0.03*).
Figure 3

mRNA expressions in human PBMC among ED and healthy controls. Error bars represents SE and significance represents * of the relative expression levels normalized against GAPDH.